| 1. |
|
|
| 2. |
|
|
| 3. |
- Hailer, Nils P., et al.
(author)
-
No generally increased risk of cancer after total hip arthroplasty performed due to osteoarthritis
- 2020
-
In: International Journal of Cancer. - : Wiley. - 0020-7136 .- 1097-0215. ; 147:1, s. 76-83
-
Journal article (peer-reviewed)abstract
- Previous studies on the risk of cancer after total hip arthroplasty (THA) contradict each other, and many are hampered by small cohort sizes, residual confounding, short observation times or a mix of indications underlying the THA procedure. We evaluated the risk of cancer after total hip arthroplasty due to osteoarthritis in a nationwide cohort by comparing cancer incidences in individuals exposed to total hip arthroplasty due to osteoarthritis and in unexposed, sex-, age- and residence matched individuals. To address some previous studies' shortcomings, information on comorbidity and socioeconomic background were obtained and adjusted for. We included 126,276 patients exposed to a cemented THA between 1992 and 2012, and 555,757 unexposed individuals. Follow-up started on the day of surgery for exposed individuals and respective date for matched, unexposed individuals, and ended on the day of death, emigration, censuring or December 31st, 2012, whichever came first. The Swedish Hip Arthroplasty Registry (SHAR), the Swedish Cancer Registry, the Swedish National Patient Registry and Statistics Sweden were accessed to obtain information on procedural details of the THA, cancer diagnoses, comorbidities, and socioeconomic background. The primary outcome measure was the occurrence of any cancer after the index date. Exposed individuals had a slightly lower adjusted risk of developing any cancer than unexposed individuals (hazard ratio [HR] 0.97; CI 0.95-0.99). The only cancer with a statistically significant risk increase in exposed individuals was skin melanoma (HR 1.15; CI 1.05-1.24). We attained similar risk estimates in analyses stratified by sex, in individuals with minimum 5 years of follow-up, in an analysis including individuals with a history of previous cancer, and in patients with cementless THA. In this study on a large and well-defined population with long follow-up, we found no increased overall risk of cancer after THA. These reassuring findings could be included in the guidelines on preoperative information given to THA patients.
|
|
| 4. |
|
|
| 5. |
- Mukka, Sebastian, et al.
(author)
-
Study protocol: The DAICY trial-dual versus single-antibiotic impregnated cement in primary hemiarthro-plasty for femoral neck fracture-a register-based cluster-randomized crossover-controlled trial
- 2022
-
In: Acta Orthopaedica. - : Medical Journals Sweden AB. - 1745-3674 .- 1745-3682. ; 93, s. 794-800
-
Journal article (peer-reviewed)abstract
- Background and purpose - Older patients with a dis-placed femoral neck fracture (FNF) are often treated with a cemented primary hemiarthroplasty (HA). The DAICY trial investigates whether high-dose dual-impregnated antibiotic -loaded cement (DIAC) including gentamicin and clindamy-cin can reduce the risk of periprosthetic joint infection (PJI) in comparison with low-dose single-impregnated gentami-cin antibiotic-loaded cement (SIAC), in patients & GE; 60 years treated with a cemented HA for a displaced FNF. Study design - The trial is a national, multicenter, reg-ister-based, cluster-randomized, crossover trial. Patients & GE; 60 years with a non-pathological, displaced FNF (Type Garden 3-4/AO 31-B2 or B3) suitable for HA according to local guidelines are eligible for inclusion. Participating orthopedic departments will be randomized to start with either SIAC (control group) or DIAC treatment (intervention group) for 2 years. After 2 years, the study departments will then change to the other treatment arm for the remaining 2 years of the study. Approximately 7,000 patients will be included. The study is pragmatic in that the choice of implant brands, sur-gical approach and peri-and postoperative protocols follow the local routines of each participating department. All out-come variables will be retrieved after linkage of the studycohort to the following Swedish registers: the Fracture Reg-ister, the Arthroplasty Register, the National Patient Register and the Prescribed Drug Registry Outcome - The primary outcome will be periprosthetic joint infection of the index joint within 1 year after surgery. Secondary outcomes will be any reoperation on the index joint, mortality within 90 days and 1 year, resistance patterns of causative bacteria in cases of PJI, and health economics. Potential added value - This trial is designed to sup-port or refute the efficacy of DIAC used in patients with a dis-placed FNF, potentially reducing PJI and resource allocation. Start of the trial and estimated duration - The DAICY trial started recruiting patients in January 2022 and will continue recruiting for approximately 4 years. Complete follow-up expected in 5 years.
|
|
